This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

IMPACT Study (Improving Measurements of Persistence on "ACtonel" Treatment)

This study has been completed.
Procter and Gamble
Information provided by:
Sanofi Identifier:
First received: December 21, 2005
Last updated: January 10, 2011
Last verified: January 2011
The primary objective of this study is to assess the impact of physician's reinforcement using bone marker data on the subject's compliance (at least 50% drug taken) and persistence on treatment after one year in postmenopausal osteoporotic women.

Condition Intervention Phase
Osteoporosis Drug: risedronate Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter Prospective Study to Assess the Impact of Physician's Reinforcement on the Subject's Compliance and Persistence on Treatment Using Feedback on Bone Markers in Previously Undiagnosed Postmenopausal Osteoporotic Women Treated With Risedronate.

Resource links provided by NLM:

Further study details as provided by Sanofi:

Primary Outcome Measures:
  • To assess the impact of physician's reinforcement using bone marker data on the treatment adherence of women with PMO. [ Time Frame: collected at week 10 and 22 ]

Secondary Outcome Measures:
  • to establish the profile of the unrecognized osteoporotic woman (PVD-, RF-) using a risk factor questionnaire for osteoporosis [ Time Frame: During the study conduct ]
  • to assess the decrease of type I collagen breakdown products(urinary NTX and serum CTX) [ Time Frame: after 10 and 22 weeks of treatment ]
  • To assess the change in BMD of both total hip and lumbar spine; [ Time Frame: at week 52 compared to baseline ]
  • osteoporosis-related genotyping. [ Time Frame: During the study conduct ]

Study Start Date: August 1999
Primary Completion Date: February 2002 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   65 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Ambulatory women,
  • Caucasian, Oriental or Multiracial
  • not previously diagnosed for osteoporosis.

Exclusion Criteria:

  • Females of black descent and for the US african american are excluded because of the very low incidence of postmenopausal osteoporosis
  • and having used oral or parenteral glucocorticoids (>= 5 mg prednisone or equivalent per day) within 3 months of starting study drug or for more than one month within six months prior to study entry.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00268632

Sponsors and Collaborators
Procter and Gamble
Study Director: Lex van de Langerijt Sanofi
  More Information

Additional Information:
Responsible Party: Medical Affairs Study Director, sanofi-aventis Identifier: NCT00268632     History of Changes
Other Study ID Numbers: HMR4003B_4001
Study First Received: December 21, 2005
Last Updated: January 10, 2011

Additional relevant MeSH terms:
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Risedronate Sodium
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Bone Density Conservation Agents
Physiological Effects of Drugs processed this record on September 20, 2017